Test Detail

French Bulldog pack: HSF4 cataract, CDPA & CDDY (IVDD risk), cystinuria, congenital hypothyroidism (CHG), DM exon 2

General · Dog

Multi-disease genetic panel for the French Bulldog bringing together five molecular tests: hereditary cataract (HSF4), chondrodysplasia and chondrodystrophy with disc risk (CDPA & CDDY), cystinuria, congenital hypothyroidism with goitre (CHG) and degenerative myelopathy (DM exon 2). The conditions affect very different systems (ocular, musculoskeletal, urinary, endocrine and neurological), so the panel is a tool for the overall management of breeding. Molecular testing is complementary to —not a substitute for— ocular, orthopaedic and thyroid examination for breeding selection.
Inheritance patternMixed: HSF4 AR; CDPA semidominant (dose/size); CDDY semidominant dose-dependent (IVDD risk); cystinuria androgen-dependent; CHG AR (one case); CMR1 (BEST1) AR; DM (SOD1) AR age-dependent
Gene / MutationHSF4 (cataract); retrogene FGF4 CFA18 (CDPA) and CFA12 (CDDY/IVDD risk); cystinuria: gene and variant to be confirmed in the French Bulldog; TPO (CHG, one case); SOD1 exon 2 (DM); BEST1 c.73C>T (CMR1)
PenetranceHSF4: high penetrance in homozygotes, juvenile bilateral cataract. CDPA: quantitative effect on leg length, present in heterozygotes. CDDY/IVDD: incomplete penetrance — the variant increases the risk of disc herniation but does not guarantee it. DM (SOD1): incomplete and age-dependent penetrance. CHG: not estimable (one case). Cystinuria: affects mainly entire males (androgen-dependent).
Codeoyri
Turnaround time15 days
Price126,89 €

Incidence

Applicable breed: French Bulldog. HSF4 documented in the breed (OMIA:001758); the remaining variants (CDDY/CDPA) are widely distributed. Reliable carrier frequencies in the Spanish breeding population are not systematically published (limited data).

Breeder management

- Genotype breeding animals before mating; the panel covers six conditions in a single sample\n- For HSF4 (recessive): do not mate two carriers — 25% affected homozygotes; carrier×clear with testing. For CHG: the test exists but the basis in the breed is a single case; decide with phenotype + test, without alarm\n- For CDPA and CDDY (dominant): heterozygotes transmit the variant to 50% of the offspring; in breeds with a chondrodystrophic standard, consider not increasing the FGF4 dose to minimise the risk of disc herniation\n- For DM: do not breed with homozygotes; carriers × clear (late onset: the test alone does not decide in young animals)\n- For cystinuria (SLC3A1 haplotype): do not mate two carriers/homozygotes; with a high allele frequency, use the test as a guide for prophylaxis\n- After a confirmed clinical case, do not repeat the parental mating and communicate the status to the buyer

Specialist notes

HSF4 cataract must be differentiated from non-genetic congenital cataracts (infectious, toxic) and from senile nuclear sclerosis. Annual ocular examination (ECVO/CERF) complements the HSF4 test. Assessment of CDDY/IVDD risk is interpreted together with conformation and weight management: the test does not predict the timing or location of the herniation. CHG must be differentiated from juvenile autoimmune hypothyroidism and from iodine deficiency. DM is a diagnosis of exclusion: rule out spinal cord compression before attributing the picture to SOD1.edular before attributing the picture to SOD1.

References

1. Mellersh et al. 2006, mutaciones HSF4 en catarata hereditaria canina (PMID 16939467)
2. Brown et al. 2017, retrogén FGF4 en CFA12: condrodistrofia y hernia discal (PMID 29073074)
3. Awano et al. 2009, SOD1 exĂłn 2 y mielopatĂ­a degenerativa (PMID 19188595)
5. Major et al. 2015, disormonogénesis tiroidea (TPO) en un Bulldog francés (PMID 26478542)
6. Cistinuria en perro y gato: revisiĂłn 2021 (PMID 34438894)
7. Mellersh et al. 2007, HSF4 y catarata precoz (no tardĂ­a) en Boston terrier (PMID 17611257)

Tests included in this pack (5)

Add to cart

← Back to the search